D-0336-2021 Class II Terminated
FDA drug recall D-0336-2021 was initiated by Noven Pharmaceuticals Inc on Apr 16, 2021 and is designated Class II. Reason for recall: Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience… The recall status is terminated (terminated Oct 11, 2024). Affected quantity: 12060 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 28, 2021
- Initiation Date
- Apr 16, 2021
- Termination Date
- Oct 11, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 12060 cartons
Product description
Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. by: Noven Therapeutics, LLC Miami, Florida 33186, NDC 68968-6675-8
Reason for recall
Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.
Distribution pattern
Nationwide within the United States
Code information
Lot #: 88584 Exp. 03/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0336-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026